CureVac
About
CureVac is a biopharmaceutical company based in Tuebingen, Germany, founded in 2000 as a pioneer in mRNA technology. The company was one of the earliest to explore messenger RNA as a therapeutic platform, long before mRNA became a household term during the COVID-19 pandemic. While its first-generation COVID vaccine candidate underperformed in clinical trials, CureVac pivoted to next-generation mRNA technologies and partnered with GSK on a second-generation COVID vaccine and other infectious disease programs. The company is publicly traded on NASDAQ and continues developing its proprietary mRNA optimization platform.
Recent news
- BioNTech announces strategic transaction to acquire CureVac in $1.25B public exchange offer 2025-06-12 · BioNTech
- CureVac receives U.S. FDA IND clearance to initiate Phase 1 clinical trial for novel mRNA-based immunotherapy in squamous non-small cell lung cancer 2025-04-07 · EQS News
- CureVac's CVGBM cancer vaccine induces promising immune responses in Phase 1 glioblastoma study at ESMO 2024 2024-09-13 · CureVac
Know CureVac?
We list a record's team, investors, portfolio and events once we can verify them. Send us what you know and we'll check it.
Suggest an edit